Valvular Heart Disease
Aortic stenosis, mitral regurgitation, and aortic regurgitation -the three you'll see most. Know the murmurs, when to echo, and when to refer for intervention.
🔍 Overview
Severity
| Parameter | Mild | Moderate | Severe |
|---|---|---|---|
| Aortic valve area (AVA) | > 1.5 cm² | 1.0–1.5 cm² | < 1.0 cm² |
| Mean gradient | < 20 mmHg | 20–40 mmHg | > 40 mmHg |
| Peak velocity | < 3 m/s | 3–4 m/s | > 4 m/s |
When to Intervene
- Symptomatic severe AS: any symptom from the classic triad → immediate referral for AVR
- Classic triad (SAD): S yncope (3-year survival without AVR) · A ngina (5-year) · D yspnea/HF (2-year). Once symptoms develop, mortality is 50% at 2 years without surgery.
- Asymptomatic severe AS with EF < 50% → AVR
- TAVR (transcatheter) now approved for all surgical risk categories PARTNER 3, 2019
⚠️ Avoid vasodilators in severe AS. Afterload reduction (nitrates, ACEi, hydralazine) can cause severe hypotension -the fixed obstruction prevents compensatory increase in CO. Also avoid rapid fluid depletion -AS patients are preload-dependent.
| Feature | Acute MR | Chronic MR |
|---|---|---|
| Cause | Papillary muscle rupture (post-MI), chordae rupture, endocarditis | Mitral valve prolapse (#1), rheumatic disease, annular dilation from LV dilation |
| LV size | Normal (no time to dilate) | Dilated (volume overload compensated) |
| LA size | Normal → pulmonary edema (no compliance) | Dilated (accommodates regurgitant volume) |
| Murmur | May be soft or absent (equalization of pressures) | Holosystolic at apex, radiates to axilla |
| Treatment | Emergent surgery. Afterload reduction (nitroprusside, IABP) as bridge. | Surgery when: symptomatic, or asymptomatic with EF ≤ 60% or LVESD ≥ 40 mm. MitraClip for high surgical risk. |
| Feature | Acute AR | Chronic AR |
|---|---|---|
| Cause | Endocarditis (valve destruction), aortic dissection, trauma | Bicuspid aortic valve, rheumatic disease, aortic root dilation (Marfan, HTN) |
| LV response | Normal size → cannot accommodate volume → pulmonary edema | Eccentric hypertrophy (LV dilation -"cor bovinum") |
| Pulse pressure | May be narrow (LV can't compensate) | Wide (bounding "water-hammer" pulse, Corrigan pulse, de Musset sign) |
| Murmur | Short early diastolic (equalization) | Blowing early diastolic at LUSB, best heard sitting up and leaning forward |
| Treatment | Emergent surgery. Nitroprusside bridge. IABP is CONTRAINDICATED in AR. | Surgery when symptomatic, or asymptomatic with EF < 55% or LVESD > 50 mm or LVIDd > 65 mm. |
⚠️ IABP is contraindicated in aortic regurgitation. The balloon inflates in diastole -this increases aortic diastolic pressure and worsens regurgitant flow back into the LV.
| Feature | Details |
|---|---|
| #1 Cause | Rheumatic heart disease (virtually always). Rare in developed countries now. |
| Pathophysiology | Stenotic MV → ↑ LA pressure → LA dilation → atrial fibrillation → pulmonary HTN → RV failure |
| Murmur | Low-pitched diastolic rumble at apex with opening snap. Best heard in left lateral decubitus. Shorter snap-to-rumble interval = more severe. |
| Key complication | Afib (from LA dilation) → high stroke risk → anticoagulate with warfarin (DOACs inferior in mechanical/rheumatic valvular disease) |
| Severity | Normal MVA ~4–6 cm². Severe MS: MVA < 1.5 cm², mean gradient > 10 mmHg |
| Treatment | Rate control (BB/CCB) + anticoagulation if Afib. Intervention: percutaneous mitral balloon commissurotomy (PMBC) if pliable valve, no significant MR, no LA thrombus. Otherwise → surgical MV replacement. |
| Feature | Details |
|---|---|
| #1 Cause | Functional/secondary -RV dilation from pulmonary HTN, LV failure, or COPD stretches the tricuspid annulus |
| Primary causes | Endocarditis (IVDU -right-sided), Ebstein anomaly, carcinoid, rheumatic, pacemaker leads |
| Murmur | Holosystolic at LLSB. ↑ with inspiration (Carvallo sign) -increased RV venous return augments regurgitant flow |
| Exam findings | Elevated JVP with prominent CV waves, pulsatile liver, peripheral edema, ascites |
| Treatment | Treat the underlying cause (pulmonary HTN, LV failure). Diuretics for volume overload. Surgery rarely needed unless primary TR with severe symptoms. |
| Lesion | Murmur | Timing | Best Heard | Key Maneuver |
|---|---|---|---|---|
| Aortic Stenosis | Crescendo-decrescendo (ejection) | Systolic | RUSB → carotids | ↓ with Valsalva (except HCM) |
| Mitral Regurgitation | Holosystolic (blowing) | Systolic | Apex → axilla | ↑ with handgrip (↑ afterload) |
| Aortic Regurgitation | Early diastolic (blowing, decrescendo) | Diastolic | LUSB, sitting up/leaning forward | Wide pulse pressure, water-hammer pulse |
| Mitral Stenosis | Low-pitched rumble with opening snap | Diastolic | Apex, left lateral decubitus | Louder with exercise (↑ flow) |
| Tricuspid Regurgitation | Holosystolic (blowing) | Systolic | LLSB | ↑ with inspiration (Carvallo sign) |
- New murmur with symptoms (dyspnea, syncope, chest pain)
- Any diastolic murmur (always pathologic)
- Any holosystolic murmur (MR or TR)
- Grade ≥ 3/6 systolic murmur
- Systolic murmur + abnormal symptoms/exam findings
- Known valve disease with change in symptoms
Benign flow murmurs (grade 1–2/6 systolic at LUSB, no radiation, no symptoms, young patient) do NOT need echo. But when in doubt -echo.
📋 On Rounds
What is the classic triad of symptomatic aortic stenosis?
SAD: Syncope, Angina, Dyspnea (HF). They appear in that order as the disease progresses. Once any symptom develops, average survival without AVR: syncope = 3 years, angina = 5 years, heart failure = 2 years. This is why symptomatic severe AS is an indication for urgent valve replacement -delay costs lives.
Why is IABP contraindicated in aortic regurgitation?
The IABP inflates during diastole to augment coronary perfusion and deflates during systole to reduce afterload. In AR, blood regurgitates from aorta into LV during diastole. IABP inflation during diastole increases aortic diastolic pressure → drives MORE blood backward through the incompetent valve → worsens regurgitation and LV volume overload. Use nitroprusside or Impella instead for hemodynamic support in acute AR.
A patient with severe aortic stenosis needs non-cardiac surgery. How do you manage this?
Severe AS + non-cardiac surgery = high perioperative risk (hypotension, HF, death). Key principles: (1) Symptomatic severe AS → defer elective surgery until valve intervention (TAVR or SAVR). (2) If surgery is urgent/emergent: proceed with invasive hemodynamic monitoring, maintain preload (avoid dehydration), avoid vasodilators and rapid HR changes, goal-directed fluid management
What is the most important echo measurement in aortic stenosis and what values define severe?
Aortic valve area (AVA) is the gold standard. Severe AS: AVA < 1.0 cm², mean gradient > 40 mmHg, peak velocity > 4 m/s. BUT these can be discordant in low-flow, low-gradient AS (low EF → low gradient despite severe stenosis). In this case, do a dobutamine stress echo: if AVA remains < 1.0 cm² as flow increases → truly severe ("fixed" stenosis → valve intervention). If AVA improves → pseudosevere (improve EF medically).
Clinical Examples
📋 Case 1, Symptomatic Severe Aortic Stenosis
Patient: 76M with progressive dyspnea on exertion and an episode of exertional syncope. Crescendo-decrescendo systolic murmur at RUSB radiating to carotids. Echo: AVA 0.6 cm², mean gradient 48 mmHg, peak velocity 4.5 m/s, EF 55%.
Key findings: Symptomatic severe AS (SAD triad: Syncope, Angina, Dyspnea). Once symptoms develop, mortality without intervention: syncope = 3-year, angina = 5-year, HF = 2-year median survival.
Management:
- Immediate referral for aortic valve replacement, do NOT delay
- Heart team discussion: TAVR vs SAVR. TAVR now approved for all surgical risk categories PARTNER 3, 2019
- TAVR preferred if: age > 65, high surgical risk, no bicuspid valve. SAVR preferred if: age < 50, bicuspid, concomitant CABG needed
- AVOID vasodilators (ACEi/nitrates) and excessive diuresis, fixed obstruction means preload-dependent
- No balloon valvuloplasty as definitive therapy (restenosis in weeks), only as bridge to TAVR/SAVR
Teaching point: Symptomatic severe AS is a surgical emergency, median survival without intervention is 2-5 years depending on symptoms. There is no effective medical therapy for AS. The only treatment is valve replacement.
📋 Case 2, Acute Severe Mitral Regurgitation
Patient: 62M, 3 days post-inferior STEMI. Sudden dyspnea, new holosystolic murmur radiating to axilla, flash pulmonary edema. BP 85/50. Echo: EF 50%, flail posterior MV leaflet, severe eccentric MR jet. BNP 4200.
Key findings: Acute severe MR from papillary muscle rupture post-MI. The posteromedial papillary muscle (single blood supply from PDA) is vulnerable in inferior MI. This is a surgical emergency, mortality without surgery approaches 75% at 24h.
Management:
- Emergent cardiac surgery consult for MV repair or replacement
- Afterload reduction: nitroprusside or IV nitroglycerin (reduces regurgitant fraction by lowering SVR)
- IABP for hemodynamic stabilization as bridge to OR (reduces afterload during systole → reduces MR)
- Inotropes (dobutamine) if cardiogenic shock
- Avoid increasing afterload (phenylephrine, vasopressin), worsens regurgitation
Teaching point: Acute severe MR is a volume + pressure emergency. The LV has not had time to dilate and compensate. Unlike chronic MR (where EF can be preserved for years), acute MR → immediate pulmonary edema and shock. Surgery is the only definitive treatment.
📋 Case 3, Mitral Stenosis with New Atrial Fibrillation
Patient: 42F immigrant from South Asia with progressive dyspnea, now palpitations. HR 142 irregularly irregular, bilateral rales. Echo: MVA 1.1 cm² (moderate-severe MS), LA diameter 5.8 cm, RV pressure 55 mmHg. No MV thrombus on TEE.
Key findings: Rheumatic mitral stenosis with new Afib. MS increases LA pressure → LA dilation → Afib. Afib causes loss of atrial kick + rapid rate → dramatically worsened hemodynamics. MS + Afib = high stroke risk (warfarin required, not DOACs).
Management:
- Rate control with IV diltiazem or beta-blocker, slower HR = longer diastolic filling time through stenotic valve
- IV furosemide for pulmonary congestion (MS causes pulmonary venous HTN)
- Anticoagulation with warfarin (NOT DOACs, valvular AF from MS requires warfarin, INR 2-3)
- Once stable: percutaneous mitral balloon commissurotomy (PMBC) if valve morphology favorable (Wilkins score ≤ 8)
- If PMBC not feasible: surgical MV repair or replacement
Teaching point: Mitral stenosis with Afib is the ONE scenario where warfarin is mandatory over DOACs. DOACs have not been studied in rheumatic MS. Rate control is more important than rhythm control, slow rates improve diastolic filling through the stenotic valve.
📣 Sample Presentation
One-Liner
"Mr. Morris is a 78-year-old presenting with exertional syncope and progressive dyspnea. Echo shows severe aortic stenosis with AVA 0.7 cm², mean gradient 52 mmHg, EF 55%. Symptomatic severe AS."
Key Points to Cover on Rounds
Symptomatic severe AS (syncope + dyspnea). AVA 0.7, mean gradient 52, EF preserved. STS score 4.2% (intermediate risk). CT surgery and structural heart consulted -candidate for TAVR vs SAVR discussion. Medical optimization: gentle diuresis for volume overload. Avoiding vasodilators and aggressive diuresis. Plan: outpatient TAVR evaluation, cardiac cath to assess coronary anatomy.
🧪 Workup
Diagnostic Evaluation -Valvular Heart Disease
Echo is the cornerstone. Every suspected valvular lesion needs echocardiography for severity grading. Additional testing depends on the clinical context and surgical candidacy.
| Test | Purpose | When to Order |
|---|---|---|
| TTE (transthoracic echo) | Valve area, gradients, regurgitation severity, EF, chamber dimensions | All suspected valvular disease. First-line imaging. |
| TEE (transesophageal echo) | Superior visualization of mitral valve, prosthetic valves, endocarditis vegetations, LA thrombus | Prosthetic valve evaluation, pre-surgical planning, suspected endocarditis with negative TTE, pre-cardioversion in AF with valvular disease |
| ECG | LVH (voltage criteria in AS), atrial fibrillation (common in MS, MR), conduction abnormalities | All patients -baseline and with any symptom change |
| BNP / NT-proBNP | Assess hemodynamic burden, detect subclinical decompensation | Baseline and trending with symptom changes. Helps time intervention in asymptomatic severe disease. |
| Exercise stress test | Unmask symptoms in "asymptomatic" severe AS or MR. Assess functional capacity and hemodynamic response. | Asymptomatic severe valve disease when surgery timing is uncertain. Contraindicated in symptomatic severe AS. |
| Cardiac catheterization | Coronary anatomy pre-operatively, hemodynamic assessment when echo is discordant | Pre-surgical evaluation (assess CAD), discrepant echo findings |
Monitoring and Follow-Up
| Setting | Monitoring | Purpose |
|---|---|---|
| Inpatient (high risk) | Continuous telemetry | Detect arrhythmias (VT, pauses, heart block). Minimum 24-48h |
| Holter monitor | 24-48h outpatient | Frequent symptoms (> 1/week). Captures rhythm during symptoms |
| Event monitor | 2-4 weeks outpatient | Less frequent symptoms. Patient-activated during episodes |
| Implantable loop recorder | Up to 3 years | Recurrent unexplained syncope. Gold standard for infrequent events. ISSUE-3 |
| Orthostatic vitals | At follow-up visits | Confirm response to treatment. SBP drop > 20 or DBP > 10 within 3 min of standing |
| Driving restrictions | Counsel at discharge | Varies by state/country. Generally no driving for weeks to months after cardiac syncope |
💊 Medications
Key Medications -Valvular Heart Disease
Mechanical valves require warfarin ONLY. DOACs are contraindicated -dabigatran caused increased thromboembolic events and bleeding in mechanical valves RE-ALIGN, 2013.
| Indication | Drug | Dose / Target | Notes |
|---|---|---|---|
| Mechanical valve anticoagulation | Warfarin (Coumadin) | Target INR 2.5–3.5 (mitral) or 2.0–3.0 (aortic bileaflet) | Warfarin ONLY. DOACs contraindicated [RE-ALIGN]. Lifelong therapy. Add ASA 81mg for additional protection. |
| AF with valvular disease (MS or mechanical valve) | Warfarin (Coumadin) | Target INR 2.0–3.0 | Warfarin, NOT DOACs. "Valvular AF" = moderate-severe MS or mechanical valve. All other AF with valve disease can use DOACs. |
| Volume overload / congestion | Furosemide (Lasix) | 20–80 mg PO/IV daily, titrate to symptoms | Diuretics for symptom relief in any valve lesion with congestion. Caution in severe AS -avoid excessive preload reduction. |
| Afterload reduction (regurgitant lesions) | ACEi/ARB (e.g., lisinopril, losartan) | Standard dosing, titrate to BP | Beneficial in chronic MR and AR with LV dysfunction or HTN. Reduces regurgitant volume. Avoid vasodilators in severe AS. |
| Rate control (MS with AF) | Beta-blockers or CCBs | Metoprolol 25–100mg BID or diltiazem 30–60mg TID | Slowing HR increases diastolic filling time -critical in MS. Avoid tachycardia. |
Endocarditis Prophylaxis
Prophylaxis indications (dental procedures involving gingival manipulation or perforation):
- Prosthetic heart valve (mechanical or bioprosthetic)
- Prior infective endocarditis
- Unrepaired cyanotic CHD (including palliative shunts/conduits)
- Cardiac transplant with valvulopathy
- Drug: Amoxicillin 2g PO 30–60 min before procedure. If PCN allergy: clindamycin 600mg PO or azithromycin 500mg PO.
⚡ Summary
Summary
Echo Is the Cornerstone
Every suspected valvular lesion needs echocardiography for severity grading. A benign flow murmur, grade 1 to 2 out of 6, systolic, at the left upper sternal border, with no radiation and no symptoms in a young patient, does not need an echo, but anything diastolic, anything with symptoms, and anything you are unsure about does.
Aortic Stenosis: Symptoms Are the Trigger
Severe is a valve area below 1.0 cm², a mean gradient above 40 mmHg, or a peak velocity above 4.0 m/s. Asymptomatic severe AS has near-normal survival; the appearance of angina, syncope or heart failure means refer for valve replacement now. Nothing medical alters the natural history.
Do Not Vasodilate Severe AS
Nitrates, ACE inhibitors and hydralazine can cause profound hypotension, because the fixed obstruction prevents a compensatory rise in cardiac output. Equally, avoid rapid fluid depletion: these patients are preload-dependent. Both errors present as sudden collapse in a patient who was stable an hour earlier.
Aortic Regurgitation: Operate on the Ventricle
Symptoms, or an EF below 55%, or an end-systolic dimension above 50 mm, or an end-diastolic dimension above 65 mm. The ventricle dilates silently for years, and once it decompensates the recovery after surgery is incomplete, which is why the echo dimensions matter as much as the symptoms. Acute severe AR, from dissection or endocarditis, is a surgical emergency with no time for medical management.
IABP Is Contraindicated in Aortic Regurgitation
The balloon inflates in diastole, which raises aortic diastolic pressure and drives more blood back into the ventricle. It worsens exactly the lesion it is being used to support. This is a classic and dangerous error in a hypotensive patient with an unrecognized AR murmur.
Mitral Regurgitation: Read the EF Differently
In MR the ventricle unloads into the low-pressure left atrium, so the EF is falsely flattering. An EF of 60% in severe MR is already impaired, which is why the surgical threshold is EF 60% or below, or an end-systolic dimension of 40 mm or more, even without symptoms. Separate primary (degenerative, valve problem, operate) from secondary (functional, ventricular problem, optimize guideline therapy first).
Mitral Stenosis Is Almost Always Rheumatic
An opening snap with a diastolic rumble, and atrial fibrillation from left atrial enlargement. Rate control is the key medical intervention, because tachycardia shortens diastole and is what causes decompensation, classically in pregnancy or with new AF. Percutaneous balloon valvuloplasty is effective in suitable anatomy, unlike in aortic stenosis where it is only a bridge.
Follow Asymptomatic Disease on a Schedule
Severe lesions need annual echocardiography; moderate every 1 to 2 years; mild every 3 to 5. Teach the patient which symptoms mean 'come back now', since the entire management strategy depends on catching the transition to symptomatic disease. Refer to a Heart Valve Team for intervention decisions, and remember endocarditis prophylaxis now applies only to the highest-risk groups.
📄 One Pager
Text version
Cardiology · One Pager
Valvular Heart Disease
Severe AS = AVA < 1.0 + symptoms → TAVR/SAVR. Severe MR = surgery when EF ≤ 60% or LVESD ≥ 40mm. Don't delay intervention.
Severe Aortic Stenosis
- AVA < 1.0 cm², mean gradient > 40 mmHg, Vmax > 4 m/s
- Symptoms: exertional dyspnea, syncope, angina
- Once symptomatic → 2-year survival ~50% without intervention
- Low-flow low-gradient: dobutamine stress echo to differentiate true vs pseudo-severe
When to Intervene
- Symptomatic severe AS → TAVR or SAVR (no medical therapy works)
- Asymptomatic severe AS + EF < 50% → surgery
- Severe MR → surgery when EF ≤ 60% or LVESD ≥ 40mm
- Acute severe MR (papillary rupture) → emergent surgery
Anticoagulation
- Mechanical valve = warfarin lifelong (DOACs contraindicated [RE-ALIGN])
- INR target: 2.5-3.5 (mitral), 2.0-3.0 (aortic)
- Bioprosthetic: warfarin × 3-6 months → then ASA only
- TAVR: DAPT × 3-6 months → then ASA
Key Drugs
No medical Rx for ASValve replacement is the only treatment
Avoid in ASVasodilators, aggressive diuresis
MR afterload reductionACEi for chronic MR
WarfarinMechanical valves only
Pitfalls
- Vasodilators in severe AS (fixed obstruction → hypotension)
- DOACs with mechanical valve [RE-ALIGN increased events]
- Missing low-flow low-gradient AS (gradient looks mild)
- Delaying surgery in asymptomatic severe with declining EF
Related Topics
ACS OverviewAortic DissectionAortic StenosisArrhythmiasAtrial FibrillationCardiac Tamponade